Leerink Partnrs Has Positive Outlook for DexCom Q4 Earnings

DexCom, Inc. (NASDAQ:DXCM) – Leerink Partnrs upped their Q4 2024 earnings estimates for shares of DexCom in a research report issued to clients and investors on Monday, November 25th. Leerink Partnrs analyst M. Kratky now expects that the medical device company will earn $0.49 per share for the quarter, up from their prior forecast of $0.48. The consensus estimate for DexCom’s current full-year earnings is $1.71 per share. Leerink Partnrs also issued estimates for DexCom’s FY2026 earnings at $2.43 EPS, FY2027 earnings at $2.72 EPS and FY2028 earnings at $3.06 EPS.

Other equities research analysts also recently issued reports about the company. Stifel Nicolaus boosted their price target on DexCom from $90.00 to $100.00 and gave the company a “buy” rating in a report on Friday, August 23rd. Oppenheimer lowered their target price on shares of DexCom from $115.00 to $105.00 and set an “outperform” rating for the company in a research note on Friday, October 25th. Raymond James reduced their price target on shares of DexCom from $115.00 to $99.00 and set a “strong-buy” rating on the stock in a research report on Friday, October 25th. StockNews.com downgraded shares of DexCom from a “buy” rating to a “hold” rating in a research report on Saturday, November 2nd. Finally, Sanford C. Bernstein increased their price objective on shares of DexCom from $82.00 to $86.00 and gave the stock an “outperform” rating in a research note on Friday, October 25th. Seven equities research analysts have rated the stock with a hold rating, eleven have issued a buy rating and one has given a strong buy rating to the company’s stock. According to MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $104.59.

DexCom Stock Up 6.9 %

Shares of DexCom stock opened at $77.83 on Tuesday. The company has a quick ratio of 2.12, a current ratio of 2.46 and a debt-to-equity ratio of 1.23. The business has a 50-day moving average price of $70.76 and a 200 day moving average price of $88.93. DexCom has a fifty-two week low of $62.34 and a fifty-two week high of $142.00. The firm has a market cap of $30.40 billion, a P/E ratio of 46.60, a P/E/G ratio of 2.23 and a beta of 1.17.

Institutional Trading of DexCom

Institutional investors and hedge funds have recently added to or reduced their stakes in the business. Tidal Investments LLC grew its position in DexCom by 68.0% in the third quarter. Tidal Investments LLC now owns 36,742 shares of the medical device company’s stock worth $2,463,000 after buying an additional 14,872 shares during the last quarter. Wilmington Savings Fund Society FSB bought a new stake in shares of DexCom during the 3rd quarter worth $381,000. World Investment Advisors LLC acquired a new position in shares of DexCom in the 3rd quarter worth $2,351,000. Sanctuary Advisors LLC raised its position in shares of DexCom by 32.2% during the third quarter. Sanctuary Advisors LLC now owns 14,835 shares of the medical device company’s stock worth $1,080,000 after purchasing an additional 3,615 shares during the period. Finally, Pine Valley Investments Ltd Liability Co raised its position in shares of DexCom by 59.2% during the third quarter. Pine Valley Investments Ltd Liability Co now owns 5,679 shares of the medical device company’s stock worth $381,000 after purchasing an additional 2,111 shares during the period. 97.75% of the stock is owned by institutional investors and hedge funds.

Insider Activity at DexCom

In other DexCom news, EVP Sadie Stern sold 4,259 shares of the business’s stock in a transaction dated Wednesday, November 20th. The shares were sold at an average price of $74.73, for a total value of $318,275.07. Following the sale, the executive vice president now directly owns 71,192 shares in the company, valued at approximately $5,320,178.16. The trade was a 5.64 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, COO Jacob Steven Leach sold 746 shares of the firm’s stock in a transaction dated Monday, September 9th. The shares were sold at an average price of $69.15, for a total transaction of $51,585.90. Following the transaction, the chief operating officer now owns 264,915 shares of the company’s stock, valued at approximately $18,318,872.25. This trade represents a 0.28 % decrease in their position. The disclosure for this sale can be found here. Insiders sold 5,431 shares of company stock worth $399,319 in the last 90 days. Corporate insiders own 0.30% of the company’s stock.

DexCom Company Profile

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.